2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-119230
    Kobe2601
    		Inhibitor 99.66%
    Kobe2601 is a Kobe0065 (HY-15716) analogue. Kobe2601 can be used to probe the Kobe family of compounds' mechanism of action.
    Kobe2601
  • HY-124808
    IMM-01
    		Agonist 99.87%
    IMM-01 is a mammalian Diaphanous (mDia)-related formins agonist that inhibits DID-DAD (diaphanous inhibitory domain-diaphanous autoregulatory domain) binding with an IC50 of 140 nM. IMM-01 acts by disrupting the autoinhibitory bond between the DID and DAD domain and thus activates formins. IMM-01 shows anticancer effects.
    IMM-01
  • HY-114569
    6-CEPN
    		Inhibitor 99.17%
    6-CEPN is a RAS inhibitor. 6-CEPN can inhibit RAS activation by binding to Icmt binding sites. 6-CEPN has anticancer activity. 6-CEPN can block cancer cells in the G1 phase. 6-CEPN can induce autophagy and necrosis of Cancer cells (Icmt: isovalerylcysteine carboxymethyltransferase).
    6-CEPN
  • HY-145962
    MRTX-EX185
    		Inhibitor
    MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and KRAS(G12D), with an IC50 of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS. MRTX-EX185 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRTX-EX185
  • HY-170428
    IPS-06061
    		Degrader
    IPS-06061 is an orally active molecule glue, that forms a ternary complex of CRBN-KRASG12D-IPS06061, and degrades KRAS G12D with a DC50 <500 nM.
    IPS-06061
  • HY-124944
    APS6-45
    		Inhibitor 99.58%
    APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.
    APS6-45
  • HY-138294
    RAS/RAS-RAF-IN-1
    		Inhibitor 99.81%
    RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity.
    RAS/RAS-RAF-IN-1
  • HY-134811
    KRAS G12D inhibitor 1
    		Inhibitor 98.45%
    KRAS G12D inhibitor 1 (example 243) is a KRAS G12D inhibitor, with an IC50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation. KRAS G12D inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    KRAS G12D inhibitor 1
  • HY-18606
    K-Ras G12C-IN-3
    		Inhibitor 99.94%
    K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.
    K-Ras G12C-IN-3
  • HY-W549903
    p67phox-IN-1
    		Inhibitor 99.80%
    p67phox-IN-1 (Formula IIIa Compound) is an inhibitor targeting the interaction between Rac GTPase and p67phox protein.
    p67phox-IN-1
  • HY-152095
    PPI-GIT1/β-Pix interaction-IN-1
    		Inhibitor 99.01%
    PPI-GIT1/β-Pix interaction-IN-1 is a potent and orally active GIT1/β-Pix protein-protein interaction (PPI) inhibitor with a KD value of 7.7 µM. PPI-GIT1/β-Pix interaction-IN-1 disrupts the GIT/PIX interaction can impact the activation of the downstream Rho GTPase Rac1 and Cdc42. PPI-GIT1/β-Pix interaction-IN-1 inhibits metastasis of gastric cancer.
    PPI-GIT1/β-Pix interaction-IN-1
  • HY-168054
    PROTAC K-Ras Degrader-3
    		Degrader
    PROTAC K-Ras Degrader-3 (compound 40) is a PROTAC degrader of K-Ras with a DC50 of ≤ 1 nM against SW620 KRAS G12D, and a GI50 of ≤ 10 nM against SW620 3D cell growth. PROTAC K-Ras Degrader-3 can be utilized in cancer research.
    PROTAC K-Ras Degrader-3
  • HY-158007
    (RS)-G12Di-1
    		Inhibitor
    (RS)-G12Di-1 is a selective, covalent inhibitor of K-Ras-G12D.
    (RS)-G12Di-1
  • HY-163939
    RGT-018
    		Inhibitor
    RGT-018 is a potent and orally active SOS1 inhibitor with anti-tumor effects. RGT-018 exerts anti-cancer cell proliferation activity by inhibiting KRAS activation.
    RGT-018
  • HY-P2360
    G12
    		98.98%
    G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12).
    G12
  • HY-N6674
    Diazepinomicin
    		Inhibitor 98.04%
    Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models.
    Diazepinomicin
  • HY-112491
    KRas G12C inhibitor 1
    		Inhibitor
    KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    KRas G12C inhibitor 1
  • HY-153413
    Kras4B G12D-IN-1
    		Inhibitor 98.01%
    Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566).
    Kras4B G12D-IN-1
  • HY-W016889
    CFL-137
    		Inhibitor 99.84%
    CFL-137 is a potent KRasG12C inhibitor. CFL-137 shows an antiproliferative effect. CFL-137 shows anticancer activity. CFL-137 has the potential for the research of lung cancer.
    CFL-137
  • HY-161066
    KRAS G13D-IN-1
    		Inhibitor
    KRAS G13D-IN-1 (compound 41) is a selective and covalently reversible inhibitor of KRASG13D (IC50: 0.41 nM). The selectivity for KRASG13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRASG13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades.
    KRAS G13D-IN-1
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.